AGP Picks
View all

Vowst market seen growing on rising recurrent C. diff cases

6 hours ago
Vowst market seen growing on rising recurrent C. diff cases
By AI, Created 14:00 UTC, Nov 19, 2026, AGP -

The Business Research Company says the Vowst market is expanding as recurrent Clostridioides difficile infections rise and microbiome-based therapies gain traction. North America held the largest share in 2025 and is expected to stay the lead region through 2026.

Why it matters: - Vowst targets recurrent C. difficile infections, a condition tied to major illness burden and hospital use. - The market’s growth points to broader demand for non-antibiotic and microbiome-based treatments. - The shift could reshape how recurrent CDI is managed after standard antibiotic therapy.

What happened: - The Business Research Company published its Vowst market report covering market size, trends and forecasts for 2026-2035. - The report says Vowst market attention is increasing because the therapy addresses recurrent Clostridioides difficile infection in adults after antibiotic treatment. - The report includes regional analysis for Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also offers a free sample and the full market report.

The details: - Vowst is a prescription medicine containing live fecal microbiota spores. - The therapy is designed to prevent recurrence of Clostridioides difficile infections in adults after antibiotic therapy. - Its mechanism is to restore beneficial gut bacteria and suppress C. diff growth. - The report cites rising recurrent C. diff infections, limits of conventional antibiotics and growing clinical validation of microbiome therapeutics as past growth drivers. - It also points to higher hospital-acquired infection rates and streamlined regulatory pathways for live biotherapeutic products. - Future growth is expected to come from microbiome-based drugs, non-antibiotic infection management solutions, more gut health research, oral biologic formulations and precision microbiome therapies. - The report identifies increasing prevalence of CDI as a key demand driver. - CDI can cause inflammation of the colon, severe diarrhea, abdominal discomfort and fever. - The report says widespread antibiotic use, healthcare-associated infections, aging populations with weaker immune systems and more virulent C. difficile strains are helping drive case growth. - Data cited from The National Library of Medicine in March 2023 says about 500,000 people in the United States get CDI each year and about 30,000 die. - North America held the largest share of the Vowst market in 2025. - North America is projected to remain the leading region through 2026 because of high CDI incidence, stronger healthcare infrastructure and faster adoption of innovative therapies.

Between the lines: - The market narrative is less about one branded drug and more about a broader move toward microbiome restoration as a clinical strategy. - Oral delivery appears to be a commercial advantage because it is simpler for patients than more complex biologic formats. - The report’s emphasis on precision microbiome therapies suggests the category is still early and likely to evolve as evidence and adoption build.

What's next: - The report expects continued market growth as microbiome-based drugs and oral live biotherapeutics advance. - Wider adoption will likely depend on clinical validation, reimbursement and how quickly hospitals and physicians shift away from antibiotic-only approaches. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel dashboards and trend analysis.

The bottom line: - Vowst sits at the center of a growing market for microbiome-based prevention of recurrent C. difficile infections, with North America still leading the way.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Consumer Products Africa

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Consumer Products Africa

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.